Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Income from Continuing Operations rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 107.49% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Income from Continuing Operations of $117.3 million as of Q3 2025, which was up 2,319.50% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Income from Continuing Operations registered a high of $117.3 million during Q3 2025, and its lowest value of -$51.9 million during Q2 2024.
  • For the 3-year period, Ligand Pharmaceuticals' Income from Continuing Operations averaged around $11.8 million, with its median value being $2.3 million (2023).
  • In the last 5 years, Ligand Pharmaceuticals' Income from Continuing Operations crashed by 2,366.86% in 2024 and then skyrocketed by 1,735.15% in 2025.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Income from Continuing Operations stood at $13.8 million in 2021, then tumbled by 205.33% to -$14.5 million in 2022, then spiked by 225.14% to $18.2 million in 2023, then plummeted by 270.93% to -$31.1 million in 2024, then surged by 1,735.15% to $117.3 million in 2025.
  • Its Income from Continuing Operations stands at $117.3 million for Q3 2025, versus $4.8 million for Q2 2025 and -$42.5 million for Q1 2025.